Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
FDA Warms 8 Companies for Unapproved Eye Items
On Monday, the US Food and Drug Administration (FDA) took action by sending warning letters to several companies, including CVS and Walgreens, due to concerns regarding the manufacturing and marketing of unapproved eye products. According to the FDA, these products…
Pioneering Glaucoma Therapy: $2M Research Grant Awarded
Researchers at Indiana University School of Medicine are embarking on a groundbreaking mission to develop a new therapy for glaucoma, a disease that can lead to blindness. This endeavor is made possible by a newly awarded five-year, $2 million R01…
Carl Zeiss Meditec to Acquire D.O.R.C.
Carl Zeiss Meditec AG announced that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from Eurazeo SE, based in Paris, France. The deal is worth €985 million (nearly…
RevOpsis Raises $16.5M for Wet AMD Treatment
RevOpsis Therapeutics has announced the successful closure of its first seed funding round, securing a total of $16.5 million. This funding is set to advance the development and commercialization of treatments for chronic multifactorial diseases through the company’s innovative, fully…
5 Dos and 5 Don’ts After Laser Eye Surgery
Laser eye surgery has become a popular solution for correcting vision problems such as nearsightedness, farsightedness, and astigmatism. While the procedure is known for its high success rate and quick recovery times, proper post-operative care is crucial to achieve optimal…
Verana Health Launches Qdata Module for TED Research
Verana Health has introduced its Qdata Thyroid Eye Disease (TED) module, a new addition to its suite of data solutions, featuring a comprehensive dataset derived from over 250,000 de-identified patients. This module is designed to enhance the extraction of diagnoses…
SalioGen Picks SGT-1001 for Stargardt Disease Development
SalioGen Therapeutics announced the selection of SGT-1001 as a development candidate for Stargardt disease treatment, a rare inherited retinal disease. This innovative therapy, SGT-1001, is designed as a one-time, non-viral intervention aimed at slowing or halting the progressive central vision…
Ocugen Completes Dosing in Key Trial for GA Treatment
Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…
10 Organizations Making a Difference in Eye Health
In the vast and complex world of healthcare, eye health often doesn’t receive as much attention as it should, despite being crucial to our quality of life. Vision problems and blindness significantly affect millions of people globally, hindering education, employment,…
New Treatment Slows Down Progression of AMD, RP
A breakthrough study has unveiled a promising advancement in the treatment of incurable eye diseases such as age-related macular degeneration and retinitis pigmentosa. Researchers have successfully integrated anti-inflammatory drugs into a hydrogel, aiming to combat inflammation in the retina while…